Search

The translation of drug delivery innovations from laboratory design to clinical application remains uncertain, expensive, and highly selective. Many systems demonstrate promising biological activity in early studies but fail to progress because evidence of manufacturability, safety, stability, or regulatory maturity is incomplete. This creates a recurring gap between technical novelty and clinical readiness. Existing technology readiness models provide useful language for describing maturity, but they were not originally designed for pharmaceutical technologies. Drug delivery systems require simultaneous assessment of material attributes, formulation behaviour, biological performance, dose reproducibility, scale-up potential, and patient-facing utility. A single linear maturity scale is therefore insufficient for classifying readiness before first-in-human development. This article develops a novel conceptual model called the Pharmaceutical Technology Readiness Matrix. The model integrates technology readiness logic, drug delivery innovation categories, and preclinical translation criteria into a structured assessment framework. Its purpose is to support transparent classification, risk assessment, and decision-making before clinical translation. The proposed matrix adapts readiness levels for drug delivery technologies, classifies major innovation categories, defines preclinical translation criteria, and links evidence maturity to risk and Go/No-Go decisions. Five tables specify the readiness levels, innovation categories, translation criteria, matrix design, and decision pathway. Together, these elements provide a practical conceptual tool for comparing heterogeneous delivery technologies. The Pharmaceutical Technology Readiness Matrix may help researchers, investors, developers, and regulators evaluate drug delivery systems more consistently. By making evidence gaps explicit before clinical translation, the model aims to reduce avoidable attrition and guide rational allocation of development resources. Future empirical validation will be required to test its predictive value across delivery platforms and therapeutic areas.

Scalable drug delivery platforms are increasingly central to pharmaceutical innovation because they can shorten development timelines, support repeated product generation, and enable broader access when manufacturing and regulatory pathways are sufficiently stable. Yet the term “platform” is often applied before a technology has demonstrated repeatable transfer across products, indications, and production environments. This creates uncertainty about whether a delivery technology is truly mature or simply promising. Existing maturity concepts offer useful starting points but do not fully capture the pharmaceutical specificity of drug delivery platforms. Generic technology readiness models tend to emphasise proof of concept, whereas manufacturing readiness frameworks focus on production capability. Pharmaceutical platform maturity requires a broader view that also includes formulation robustness, patient-facing performance, quality system integration, regulatory precedent, and lifecycle adaptability. This article develops a conceptual model for defining and assessing pharmaceutical platform maturity in scalable drug delivery technologies. The proposed Pharmaceutical Platform Maturity Model integrates product-level, process-level, and regulatory-level maturity into a single interpretive framework. The model is designed to distinguish early innovation from repeatable platform capability. The model defines scalable delivery technology criteria, identifies maturity indicators across three interdependent dimensions, and proposes a five-level maturity scale ranging from concept to commoditised platform. Four tables support the argument by contrasting existing assessment frameworks, defining scalability criteria, summarising maturity indicators, and presenting the integrated maturity rubric. The model is intended as a strategic, analytical, and communicative tool. The article concludes that platform maturity should not be inferred from clinical success, manufacturing feasibility, or regulatory approval alone. A drug delivery platform becomes mature only when product performance, process control, and regulatory confidence co-evolve into a repeatable system. This integrated perspective can help developers, investors, regulators, and technology assessors evaluate scalable delivery technologies more consistently.